The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 35.25
Bid: 35.00
Ask: 35.50
Change: 0.00 (0.00%)
Spread: 0.50 (1.429%)
Open: 35.25
High: 35.25
Low: 35.25
Prev. Close: 35.25
CREO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Call Option Agreement

21 Nov 2008 09:24

RNS Number : 6520I
China Real Estate Opportunities Ltd
21 November 2008
 

China Real Estate Opportunities Limited

 

CREO ANNOUNCES CALL OPTION IN RREEF CHINA COMMERICIAL TRUST

 

21 November 2008, Hong Kong - China Real Estate Opportunities Limited ("CREO" or the "Company"), an AIM listed property company with an established investment and development portfolio in China today announced that it had entered into a call option agreement to acquire a 25.65% stake or 119,043,500 units in RREEF China Commercial Trust ("RREEF CCT"), a Hong Kong-listed Real Estate Investment Trust ("REIT"), to be exercised on 12 January 2009 at a cost of HKD 387 million (£33.6 million). 

RREEF CCT listed on the Hong Kong Stock Exchange on 22 June 2007 and currently owns an international grade A office and retail complex in the Chaoyang District of Beijing. The property, Beijing Gateway Plaza, is a strongly performing commercial real estate asset of approximately 130,000 square metres, with occupancy of over 95%, and is entirely consistent with CREO's long-term investment and operating philosophy.

RREEF CCT is managed by RREEF China Reit Management Limited, which is owned by RREEF Alternative Investments through Deutsche Bank Asia Pacific.

As at June 2008, RREEF CCT had a net asset value (NAV) of HKD6.04 per share, whilst the individual asset had a gross property value of HKD8.56 per share (HKD3.99 billion, £347.0 million). An interim dividend of HKD18.63 cents per share was paid in June 2008. Based on the share price of HKD1.880 on 20 November 2008, RREEF CCT had a market capitalisation of HKD873 million (£75.9 million). 

CREO has secured the call option at HKD3.25 per share representing a 46% discount to NAV and 62% discount to gross property valueBased on the interim dividend outlined in the June 2008 interim accounts the exercise price of the call option of HKD3.25 equates to a dividend yield of 11.5% per annum.

Mr. Ray Horney, Chairman of China Real Estate Opportunities Limited said, "This transaction reinforces CREO's ongoing commitment to its core business and exhibits its capacity to identify strategic investments that maintain its position as one of the leading foreign investors in China's commercial real estate market and that are accretive to its existing investments".

-- Ends --

About CREO

CREO was listed on the AIM market in London on 11th July 2007 under ticker symbol CREO, having successfully raised £259 million. Harnessing the intimate local market knowledge and key relationships that Treasury Holdings has been able to develop through its presence in China since 2002, CREO's principal objective is to maximise capital growth from a portfolio of properties in China. The projects will all incorporate high quality design, specifications, and finishes synonymous with Treasury Holdings.

CREO, with an exclusive focus on the China real estate market currently owns seven high-quality, strategically located properties in ShanghaiBeijing, and Qingdao. The company's main focus is in the commercial real estate sector, with income-producing properties currently representing 75% of the total portfolio.

www.china-reo.com

www.treasuryholdings.com

For further information, please contact:

CREO

Ray Horney, Chairman

Tel: + 44 (0)1273 775225

Sarah Moriarty, Investor Relations 

Tel: +353 1 6189455

Treasury Holdings China 

Richard David, Managing Director

Tel: (+86) 21 6282 5000 

Davy

Des Carville

Tel: +353 1 679 6363

Media Enquiries:

Bankside Consultants

Simon Rothschild, Oliver Winters

Tel: + 44 (0)207 367 8888

Murray Consultants

Ed Micheau

Tel: + 3531 498 0300

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGREAPFFADAPFEE
Date   Source Headline
21st Feb 202310:29 amRNSHolding(s) in Company
17th Feb 20232:05 pmRNSSecond Price Monitoring Extn
17th Feb 20232:00 pmRNSPrice Monitoring Extension
17th Feb 202312:10 pmRNSLaunch of Open Offer and Posting of Circular
16th Feb 20236:04 pmRNSResult of Placing and Subscription
16th Feb 20239:05 amRNSSecond Price Monitoring Extn
16th Feb 20239:00 amRNSPrice Monitoring Extension
16th Feb 20237:00 amRNSPlacing and Subscription to raise a minimum £25m
15th Feb 202311:05 amRNSSecond Price Monitoring Extn
15th Feb 202311:00 amRNSPrice Monitoring Extension
30th Jan 20238:51 amRNSAward of Shares under Share Incentive Plan
23rd Jan 202311:47 amEQSCreo Medical (CREO): Progressing on all fronts
18th Jan 20232:05 pmRNSSecond Price Monitoring Extn
18th Jan 20232:00 pmRNSPrice Monitoring Extension
11th Jan 20237:00 amRNSFY 2022 Trading Update
16th Dec 20222:05 pmRNSSecond Price Monitoring Extn
16th Dec 20222:00 pmRNSPrice Monitoring Extension
1st Dec 20222:12 pmRNSHolding(s) in Company
24th Oct 20227:00 amRNSKamaptive Licence and Royalty Agreement with CMR
30th Sep 20227:00 amRNSTotal Voting Rights
23rd Sep 20227:00 amRNSExercise of Options
23rd Sep 20227:00 amRNSExercise of Options
22nd Sep 20227:00 amRNSChris Hancock elected as a Fellow of Royal Academy
9th Sep 20227:00 amRNSHalf-year Report
5th Sep 20227:00 amRNSNotice of Results
31st Aug 20227:00 amRNSTotal Voting Rights
8th Aug 20227:00 amRNSLTIP Awards and PDMR Dealing
4th Aug 20227:00 amRNSExercise of Options
3rd Aug 20227:00 amRNSH1 2022 Trading Update
2nd Aug 20227:00 amRNSAward of Shares under Share Incentive Plan
28th Jun 202212:33 pmRNSResult of AGM
28th Jun 20227:00 amRNSAGM Statement
27th May 20227:00 amRNSDirector/PDMR Shareholding
26th May 20227:00 amRNSPosting of 2021 Annual Report and Accounts
23rd May 20227:01 amRNSFinal Results
23rd May 20227:00 amRNSCollaboration agreement with Intuitive
18th May 20223:22 pmRNSHolding(s) in Company
17th May 20227:00 amRNSNotice of Results
28th Apr 20227:00 amRNSTrading update and notice of results
20th Apr 20227:00 amRNSOpening of Singapore regional hub
5th Apr 20227:00 amRNSCTO wins Technology Innovator of the Year Award
16th Mar 20227:00 amRNSAlbyn Medical earn out update
28th Feb 20227:00 amRNSTotal Voting Rights
7th Feb 20227:00 amRNSPresentation at Growth and Innovation Forum 2022
4th Feb 20227:00 amRNSAward of Shares under Share Incentive Plan
3rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20224:35 pmRNSPrice Monitoring Extension
3rd Feb 20227:00 amRNSTrading update
24th Jan 20227:00 amRNSLicensing & Partnership update
31st Dec 20217:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.